Can Acadia Pharmaceuticals cover its short-term obligations?

Its current ratio is 3.59 — current assets exceed current liabilities.

Where does Acadia Pharmaceuticals's balance sheet data come from?

Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Acadia Pharmaceuticals ACAD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$282.21M+58.8%	$177.7M-31.1%	$258M+1.7%	$253.64M+16.5%	$217.7M-31.9%
Short-term investments	$569.25M-11.3%	$641.99M+9.0%	$589.02M+15.9%	$508.36M+9.6%	$463.88M+6.3%
Restricted cash	$7.85M0.0%	$7.85M-17.2%	$9.47M0.0%	$9.47M+8.0%	$8.77M0.0%
Accounts receivable, net	$135.35M+11.4%	$121.46M+4.8%	$115.85M+7.8%	$107.51M+1.7%	$105.74M+7.1%
Inventories	-$78K-102%	$4.89M—	$0-100%	$4.1M-60.8%	$10.45M+136%
Work in process	$80.72M+5.2%	$76.7M-0.2%	$76.89M-8.9%	$84.4M+5.5%	$80.03M+14.7%
Accrued investment income	$13.03M-51.3%	$26.77M+13.5%	$23.59M+93.6%	$12.18M+52.8%	$7.97M+33.8%
Total current assets	$1.1B+3.2%	$1.06B-1.3%	$1.08B+12.1%	$960.55M+10.3%	$870.94M-7.2%
Property and equipment, net	$14.65M+95.1%	$7.51M+103%	$3.71M+4.5%	$3.55M+1.4%	$3.5M-17.0%
Operating lease right-of-use assets	$46.27M-2.3%	$47.35M-4.7%	$49.67M-2.6%	$50.99M+0.7%	$50.61M+8.7%
Intangible assets, net	$106.17M-2.5%	$108.89M-2.4%	$111.62M-2.4%	$114.34M-2.3%	$117.06M-2.3%
Deferred tax assets	——	——	——	——	——
Other non-current assets	$3.93M+0.8%	$3.9M+30.1%	$2.99M+32.9%	$2.25M+54.8%	$1.46M+305%
Total assets	$1.61B+2.6%	$1.56B+17.5%	$1.33B+8.6%	$1.23B+8.2%	$1.13B-4.7%
Accrued expenses	$293.28M+10.2%	$266.21M-20.5%	$334.84M+8.0%	$309.93M+9.0%	$284.44M-24.9%
Operating lease liabilities, current	$11.79M+1.4%	$11.63M-1.3%	$11.78M+0.8%	$11.69M+2.8%	$11.37M+14.2%
Total current liabilities	$305.52M+10.3%	$277.11M-22.3%	$356.58M+8.0%	$330.02M+9.1%	$302.53M-23.4%
Operating lease liabilities, non-current	$39M-3.8%	$40.55M-5.7%	$43.03M-3.5%	$44.6M-0.1%	$44.63M+6.2%
Operating Lease Liabilities (Total)	$50.79M-2.7%	$52.19M-4.8%	$54.81M-2.6%	$56.29M+0.5%	$56.01M+7.7%
Other non-current liabilities	$12.64M-34.0%	$19.14M+37.8%	$13.89M-51.3%	$28.55M+43.0%	$19.96M+10.6%
Total liabilities	$357.16M+6.0%	$336.81M-18.5%	$413.5M+2.6%	$403.17M+9.8%	$367.13M-19.3%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	$16K0.0%	$16K0.0%	$16K0.0%	$16K0.0%	$16K0.0%
Additional paid-in capital	$3.06B+0.6%	$3.04B+1.2%	$3B+0.8%	$2.98B+1.0%	$2.95B+0.5%
Retained earnings	-$1.81B+0.2%	-$1.81B+13.1%	-$2.09B+3.3%	-$2.16B+1.2%	-$2.19B+0.9%
Accumulated other comprehensive income (loss)	-$563K-139%	$1.45M+46.1%	$989K+144%	$406K-7.1%	$437K+49.7%
Total stockholders' equity	$1.25B+1.7%	$1.23B+33.8%	$917.27M+11.5%	$822.38M+7.5%	$765.24M+4.4%
Total liabilities and stockholders' equity	$1.61B+2.6%	$1.56B+17.5%	$1.33B+8.6%	$1.23B+8.2%	$1.13B-4.7%
Available For Sale Securities Debt Securities Current	$569.25M-11.3%	$641.99M+9.0%	$589.02M+15.9%	$508.36M+9.6%	$463.88M+6.3%
Deferred Tax Assets and Other Non-Current Assets	$3.93M+0.8%	$3.9M+30.1%	$2.99M+32.9%	$2.25M+54.8%	$1.46M+305%
Net Investment in Lease	$46.27M-2.3%	$47.35M-4.7%	$49.67M-2.6%	$50.99M+0.7%	$50.61M+8.7%
Deferred tax assets	——	——	——	——	——
Intangible assets — net	$106.17M-2.5%	$108.89M-2.4%	$111.62M-2.4%	$114.34M-2.3%	$117.06M-2.3%
Operating lease right-of-use assets	$46.27M-2.3%	$47.35M-4.7%	$49.67M-2.6%	$50.99M+0.7%	$50.61M+8.7%
Other non-current assets	$3.93M+0.8%	$3.9M+30.1%	$2.99M+32.9%	$2.25M+54.8%	$1.46M+305%
Short Term Inventory	$31.57M-8.9%	$34.67M+19.2%	$29.1M+11.4%	$26.12M+13.8%	$22.95M+4.6%
Operating Lease Right-of-Use Assets in Other Assets	$46.27M-2.3%	$47.35M-4.7%	$49.67M-2.6%	$50.99M+0.7%	$50.61M+8.7%
Software and Technology Licenses, Net	$3.93M+0.8%	$3.9M+30.1%	$2.99M+32.9%	$2.25M+54.8%	$1.46M+305%
Other Commercial Liabilities	$293.28M+10.2%	$266.21M-20.5%	$334.84M+8.0%	$309.93M+9.0%	$284.44M-24.9%
Accrued Liabilities, Current	$293.28M+10.2%	$266.21M-20.5%	$334.84M+8.0%	$309.93M+9.0%	$284.44M-24.9%
Total debt	$50.79M-2.7%	$52.19M-4.8%	$54.81M-2.6%	$56.29M+0.5%	$56.01M+7.7%
Additional paid-in capital	$3.06B+0.6%	$3.04B+1.2%	$3B+0.8%	$2.98B+1.0%	$2.95B+0.5%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$16K0.0%	$16K0.0%	$16K0.0%	$16K0.0%	$16K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Interest receivable on interest rate and cross currency swaps	$13.03M-51.3%	$26.77M+13.5%	$23.59M+93.6%	$12.18M+52.8%	$7.97M+33.8%
Inventory For Long Term Contracts Or Programs	$80.72M+5.2%	$76.7M-0.2%	$76.89M-8.9%	$84.4M+5.5%	$80.03M+14.7%
Prepaid expenses	$64.6M+8.5%	$59.53M-2.2%	$60.87M+15.4%	$52.75M+0.1%	$52.7M-5.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Acadia Pharmaceuticals cover its short-term obligations?: Its current ratio is 3.59 — current assets exceed current liabilities.
Where does Acadia Pharmaceuticals's balance sheet data come from?: Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.